Share buyback program — GSK shows bullish momentum above key moving averages

Traders Union
All News
Financial News
GSK rises 0.84% today to GBX 1,806

Highlights

GSK repurchased 250,000 ordinary shares on November 28, 2025, through BNP Paribas as part of its ongoing share buyback program.
Following the transaction, GSK's total shares held in treasury rose to 236,608,577, emphasizing its active capital structure management.
The share buyback is integral to GSK's capital management strategy, signaling continued commitment to shareholder value and balance sheet optimization.

Treasury share count rises as buyback underscores capital strategy

GSK announced the repurchase of 250,000 ordinary shares as part of its ongoing share buyback program. The transaction, executed through BNP Paribas on November 28, 2025, supports the company’s capital structure and increases the total number of shares held in treasury to 236,608,577. This buyback activity is integral to GSK's capital management strategy.

Sustained bullish signals strengthen as volatility remains contained

GBX 1,806.00 is trading above the MA-20 (GBX 1,789.98), MA-50 (GBX 1,687.02), and MA-200 (GBX 1,500.05), confirming bullish momentum across short-, medium-, and long-term trends. The nearest support is the Ichimoku Kijun at GBX 1,713, while resistance emerges at the MA-50 extended to the next round level near GBX 1,850.

Momentum indicators show sustained buyer strength, as both MACD and ADX remain firmly bullish. RSI on D1 reads 58.5 (not overbought), while Stoch RSI signals an oversold condition and CCI is neutral, indicating mixed oscillator sentiment. Bull/Bear Power remains positive and overbought, reflecting dominant buyer pressure intraday. The Awesome Oscillator supports the prevailing uptrend. Today’s session saw a minor opening gap and a 0.84% advance, with the price currently positioned near the mid-to-high end of today’s range — volatility is moderate, and the tone reflects strength toward session highs. Divergences between oscillators and trend momentum suggest some hesitation, but price action and momentum remain broadly aligned.

Upside probability rises as technical momentum bolsters price outlook

For the next 5 trading days, the expected price range is GBX 1,815–1,900, adjusted for a typical volatility band relative to current levels. The probability of a price increase is very high (more than 80%) due to strong buy signals across all major weekly indicators, making a decrease much less likely. Baseline scenario: the price consolidates between support at GBX 1,715 and resistance near GBX 1,850–1,900. Bullish scenario: a break above GBX 1,850 could open the way toward the upper range near GBX 1,900. Bearish scenario: failure to hold above GBX 1,715 exposes the market to pullbacks towards weekly support closer to GBX 1,700.

Anton Kharitonov, analyst at Traders Union, believes GSK remains in a positive trend, supported by strong technicals and ongoing buyback activity. He notes that while indicators show momentum, mixed oscillator signals and moderate volatility warrant caution. The base case is consolidation unless price fails at key support. "Until GBX 1,715 breaks, I remain defensive and wait for clearer trend confirmation."

Previously it was reported that GSK exhibited sustained strength across all major moving averages, with the price holding above key trend levels as technical indicators like MACD and ADX signaled active bullish momentum. Oscillators showed mixed signals — with the RSI nearing overbought territory and short-term sideways movement suggesting caution in the immediate term.

Source of Data: GSK Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.